Last $14.57 USD
Change Today -0.21 / -1.42%
Volume 79.7K
PETX On Other Exchanges
As of 5:20 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/13 - $29.32
52 Week Low
08/30/13 - $8.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

No Related Businessweek News Found

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

25 Employees
Last Reported Date: 03/26/14
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $50.7K
Chief Development Officer
Total Annual Compensation: $286.1K
Chief Commercial Officer
Total Annual Compensation: $270.6K
Chief Scientific Officer
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics, Inc. Appoints Robert P. Roche to its Board of Directors

Aratana Therapeutics, Inc. announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors.

Aratana Therapeutics, Inc. Presents at Guggenheim Animal Health Day, Jun-23-2014

Aratana Therapeutics, Inc. Presents at Guggenheim Animal Health Day, Jun-23-2014 . Venue: New York, New York, United States.

Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-Cell Lymphoma

Aratana Therapeutics, Inc. announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma. These studies are not required by the USDA to obtain a full product license for AT-005, for which it is currently under review. They were designed by veterinary oncologists to evaluate AT-005 under real practice conditions, which will help Aratana and oncologists understand the clinical value of AT-005 once it is fully licensed by the USDA, which is anticipated to be in 2015. Specifically, the studies will evaluate AT-005 in combination with two different chemotherapy regimens used to treat dogs diagnosed with intermediate- to high-grade peripheral T-cell lymphoma. The studies are being conducted in coordination with Animal Clinical Investigation, LLC (ACI). Details are as follows: T-CHOMP (T cell -- CHOP + Monoclonal antibody) Patient dosing has initiated in this randomized, blinded, placebo-controlled field study, which will enroll an estimated 48 client-owned dogs and is designed to assess the benefit of adding AT-005 to multi-agent CHOP chemotherapy (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone). All patients will receive standard CHOP chemotherapy and will be randomized (1:1) to receive supplemental AT-005 or placebo. Patients will be dosed twice weekly for four weeks, once weekly for another 15 weeks, and monthly thereafter. The study duration is 18 months; however, if progressive disease occurs before the 18-month visit, dogs will be removed from the study at that time. The primary efficacy endpoint is progression-free survival (PFS), with a secondary endpoint of objective response rate (ORR). Investigators will also monitor patients for overall survival (OS). Adverse events will be evaluated and compared between treatment and placebo groups. T-LAB (T cell -- Lomustine + monocolonal AntiBody). This randomized, blinded, placebo-controlled field study will enroll an estimated 60 client-owned dogs, and is designed to assess the benefit of adding AT-005 to single-agent lomustine (CCNU) chemotherapy. All patients will receive two three-week cycles of single-agent CCNU chemotherapy, after which patients that achieve partial or complete response will be randomized (1:1) to receive AT-005 or placebo twice per week for the next four weeks. Patients will continue to receive AT-005 or placebo every other week for another 8 weeks, after which they will be rechecked monthly. The total study duration is 12 months; however, patients will be removed from the study if their disease progresses before the 12-month visit. The primary efficacy endpoint is progression-free survival (PFS) and investigators will also monitor the duration of response and overall survival (OS). Adverse events will be evaluated and compared between treatment and placebo groups.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $14.57 USD -0.21

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $16.02 USD -0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,323.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,138.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at